Cancer Therapy

NCI study with Delcath System shows early promise

Published in Cancer Weekly, January 14th, 2003

Delcath Systems, Inc., (DCTH) reported that 75% of patients who completed all planned treatments with its experimental cancer technology at the National Cancer Institute (NCI) achieved results ranging from disease stabilization to complete response.

In a report to the company, NCI researchers further said that 4 of 11 patients enrolled in its dose-finding study had undergone all four planned treatments. Results in three of the patients included a complete response, a partial response, and disease stabilization.

At press time, the fourth patient was awaiting response assessment.

With regard to the other seven patients:

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-01-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry